E25Bio, a Cambridge, Mass.-based provider of rapid, point-of-care, diagnostic technology, raised $2.3m in seed funding.
The round was led by The Engine, with participation from Alumni Ventures Group and angel investor Alejandro Chavez.
Founded in 2018 by Jeff Takle, CEO, based on technology developed by Drs. Irene Bosch and Lee Gehrke and licensed from MIT, E25Bio is developing rapid diagnostic test technology for at-home-use that can detect dangerous infectious diseases such as the acute febrile illnesses in minutes instead of days.
The first product is an over-the-counter test for patients appearing with fever, which is able to screen for active viruses and enables a more rapid and accurate diagnosis of infectious diseases in time to receive potentially life-saving treatment.
E25Bio has completed clinical studies and has initiated regulatory submission in its first target geographies.
FinSMEs
26/08/2019